- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01493011
Chemotherapy Combined With Whole-body Hyperthermia to Treat Stage IIIB/IV Non Small Cell Lung Cancer (WBH&NSCLC)
May 13, 2012 updated by: Xijing Hospital
A Randomized Contrasted Polycentric Clinical Study About Chemotherapy Combined With Whole-body Hyperthermia(WBH)to Treat Stage IIIB/IV Non Small Cell Lung Cancer (NSCLC)
Millions of patients die of non-small cell lung cancer (NSCLC) every year.
There are several methods to treat NSCLC, including surgery, chemotherapy, radiotherapy and bioimmuotherapy.
Recently, hyperthermia therapy has played an important role in neoplasm therapy.
It has showed some effect in NSCLC both in animal experiment and clinical practice, yet there is little literature about Whole-body Hyperthermia (WBH) with neoplasm.
The investigators decides to develop this randomized contrasted multicenter clinical study to testify to the effect of chemotherapy combined with WBH to treat stage IIIB/IV Non Small Cell Lung Cancer (NSCLC).
Study Overview
Status
Unknown
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
120
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: LIU WENCHAO, professor
- Phone Number: 029-84775407
- Email: liuch@FMMU.edu.cn
Study Locations
-
-
Shanxi
-
Xi'an, Shanxi, China, 710031
- Recruiting
- Xijing Hospital
-
Contact:
- GUO JUNZHAO, DOCTOR
- Phone Number: 029-84775412
- Email: ADermenguo@126.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Older than 18, survive more than 3 months;
- Pathologically or cytologically proven stage IIIB/IV non small cell lung cancer(NSCLC);
- Measurable disease, defined as lesions that can be accurately measured in at least one dimension (longest diameter to be recorded) as ≥ 2 cm with conventional techniques or as ≥ 1 cm with spiral CT scan No known CNS tumors, including brain metastases;
- ECOG performance status 0-2;
- Granulocytes ≥ 1,500/μL Platelets ≥ 75,000/μL Hemoglobin ≥ 8.5 g/dL Bilirubin ≤ 3 mg/dL ALT and AST ≤ 2 times upper limit of normal (ULN) PT/INR ≤ 1.7 (therapeutic anticoagulation [e.g., coumadin or heparin] allowed provided there is no prior evidence of underlying abnormality in these parameters) Creatinine ≤ 1.5 times ULN OR creatinine clearance ≥ 60 mL/min;
- Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception before, during, and for 30 days after completion of study therapy;
- Other prior adjuvant therapy is allowed provided it was completed > 6 months ago AND there is documented recurrence of NSCLC;
- No prior local therapy for the target lesion unless the target lesion located within the field of local therapy has shown ≥ 25% increase in size since last treatment;
- At least 4 weeks since prior and no concurrent palliative radiotherapy No concurrent combination anti-retroviral therapy for HIV;
- volunteers who signed informed consent.
Exclusion Criteria:
- During Screening period and treatment period, the main target for lesions has been given radiation;
- The body has metal material, including a metal JieYuHuan/support/operation fixed material within;
- Existing cerebrovascular diseases and central nervous system tumors, including metastatic carcinoma;
- Patients with recent or ongoing gastrointestinal bleed may not be transfused to reach the entry hemoglobin of 8.5 g/dL Physicians should ensure patients requiring transfusion prior to registration do not have an occult or clinically apparent gastrointestinal bleed No history of bleeding diathesis;
- No significant history of cardiac disease, including any of the following: NYHA class III-IV congestive heart failure Myocardial infarction within the past 6 months Cardiac arrhythmias requiring anti-arrhythmic therapy (other than beta blockers or digoxin) LVEF < 45% (or below the normal limit at the individual institution) by scintigraphy (MUGA or myocardial scintigram) History of hypertension allowed provided it is well controlled (i.e., BP < 140/90 mm Hg) on a regimen of anti-hypertensive therapy
- Other prior adjuvant therapy is allowed provided it was completed > 6 months ago AND there is documented recurrence of NSCLC
- No prior systemic therapy for metastatic disease At least 4 weeks since prior locoregional therapy (e.g., embolization, chemoembolization [except with doxorubicin hydrochloride], radiotherapy, or radioactive microspheres)
- No prior local therapy for the target lesion unless the target lesion located within the field of local therapy has shown ≥ 25% increase in size since last treatment
- poor Compliance, not receiving medication or follow-up according to study plan;
- There are other serious situations contrary to the scheme
- Existing tuberculosis;
- Exist two or multiple tumors
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: SINGLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: chemotherapy & WBH
Standard chemotherapy protocol combined with whole body hyperthermia
|
standard first-line chemotherapy combined with whole-body hyperthemia to treat stage Ⅲb/Ⅳ NSCLC
|
NO_INTERVENTION: chemotherapy
standard chemotherapy protocol for advanced NSCLC
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Progression-free survival (PFS)
Time Frame: one year
|
one year
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Toxicity as assessed by NCI CTC v3.0
Time Frame: one year
|
one year
|
overall suivival
Time Frame: one year
|
one year
|
quality of life
Time Frame: one year
|
one year
|
Disease Control Rate
Time Frame: one year
|
one year
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Chair: LIU WENCHAO, PROFESSOR, Xijing hospital of the fourth military medical univercity
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
November 1, 2011
Primary Completion (ANTICIPATED)
December 1, 2012
Study Completion (ANTICIPATED)
December 1, 2015
Study Registration Dates
First Submitted
December 7, 2011
First Submitted That Met QC Criteria
December 13, 2011
First Posted (ESTIMATE)
December 15, 2011
Study Record Updates
Last Update Posted (ESTIMATE)
May 15, 2012
Last Update Submitted That Met QC Criteria
May 13, 2012
Last Verified
May 1, 2012
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- FMMU
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Toxicity Due to Chemotherapy
-
Radboud University Medical CenterErasmus Medical Center; Medisch Centrum LeeuwardenRecruitingCancer | Physical Activity | Toxicity Due to Chemotherapy | Systemic TreatmentNetherlands
-
Wellstat TherapeuticsApproved for marketing
-
Michael von WolffUniversity of BernNot yet recruitingCancer | Fertility Issues | Effects of Immunotherapy | Toxicity Due to Chemotherapy | Toxicity Due to Radiotherapy | Fertility Preservation
-
University Medical Center GroningenRecruitingToxicity Due to Chemotherapy | Cancer, Treatment-Related | Cardiovascular MorbidityNetherlands
-
RWTH Aachen UniversityTechnion, Israel Institute of TechnologyUnknownToxicity Due to ChemotherapyGermany
-
Centre Hospitalier Metropole SavoieUniversité Savoie Mont BlancNot yet recruitingSarcopenia | Oncology | Toxicity Due to Chemotherapy | Physical Inactivity
-
Neuromed IRCCSCompletedToxicity Due to RadiotherapyItaly
-
National Cheng-Kung University HospitalChina Medical University Hospital; Taipei Veterans General Hospital, Taiwan; Kaohsiung... and other collaboratorsRecruitingGastric Cancer | Gastric Adenocarcinoma | Toxicity Due to Chemotherapy | Effects of ChemotherapyTaiwan
-
Hadassah Medical OrganizationUnknownFemale Patients Aged 5-35 Prior to Systemic Chemotherapy | With Significant Risk of Ovarian ToxicityIsrael
-
University Clinical Centre, GdanskNutricia FoundationUnknownQuality of Life | Metastatic Colorectal Cancer | Toxicity Due to Chemotherapy | Dietary Modification | Cancer CachexiaPoland
Clinical Trials on chemotherapy & WBH
-
Massachusetts General HospitalNational Institute of General Medical Sciences (NIGMS)RecruitingInflammation | Hyperthermia | Major Depressive DisorderUnited States
-
University of ArizonaTerminatedDepression | PTSD | Fibromyalgia | Anxiety | Chronic Fatigue SyndromeUnited States
-
University of California, San FranciscoNational Center for Complementary and Integrative Health (NCCIH)RecruitingDepression | Major Depressive DisorderUnited States
-
University of California, San FranciscoNational Center for Complementary and Integrative Health (NCCIH)CompletedMajor Depressive DisorderUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedAdult Acute Myeloid Leukemia | Adult Myelodysplastic SyndromeUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingColorectal Adenocarcinoma | Stage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Colorectal Carcinoma Metastatic in the LungUnited States, Canada
-
Cancer Institute and Hospital, Chinese Academy...Unknown
-
International Atomic Energy AgencyCompletedNon Small Cell Lung CancerChile, China, Croatia, Egypt, India, Malaysia, Malta, Morocco, Pakistan, Panama, Peru, South Africa, Tunisia
-
Ping LiangNot yet recruitingChemotherapy | Liver Metastases | Colorectal Carcinoma
-
Second Affiliated Hospital, School of Medicine,...UnknownUnresectable Gastric Cancer | Successful Conversion Rate of OperationChina